Alnylam Pharmaceuticals, Inc.
ALNY
$221.20
$4.221.95%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 382.70% | 347.87% | 224.76% | 123.13% | -291.84% |
| Total Depreciation and Amortization | -3.08% | -4.78% | -1.79% | 139.68% | 70.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 39.94% | 35.92% | 32.51% | 46.63% | -6.69% |
| Change in Net Operating Assets | -132.09% | -69.22% | -119.87% | -863.61% | -282.65% |
| Cash from Operations | 2,236.74% | 1,562.51% | 6,093.25% | 324.26% | -111.14% |
| Capital Expenditure | -151.57% | -136.37% | -71.24% | -9.90% | 31.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 324.85% | 288.70% | 699.57% | 276.11% | 67.97% |
| Cash from Investing | 167.65% | 360.14% | 473.44% | 238.08% | 61.15% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -39.56% | -34.50% | -17.47% | -17.80% | 28.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 270.86% | 255.28% | 300.74% | -1,016.07% | -194.30% |
| Cash from Financing | -236.33% | -199.46% | -194.94% | -197.09% | 10.63% |
| Foreign Exchange rate Adjustments | -140.97% | 57.69% | 329.25% | 80.73% | 551.88% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 310.33% | 104.48% | 348.83% | 480.05% | -53.52% |